Cellectar Biosciences, Inc. (CLRB) shareholders
Close on Nov 13, 2026Market cap $10.78MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Salamon Steven A J Joint filing with Rosalind Advisors, Inc. (9.90%), Aharon Gil (9.90%) and 1 more | 7,472,745 | 9.90% | 13G (passive) amendment | Dec 31, 2024 |
| Nantahala Capital Management, LLC Joint filing with Wilmot B. Harkey (5.73%), Daniel Mack (5.73%) | 2,507,125 | 5.73% | 13G (passive) amendment | Dec 31, 2024 |
| ADAR1 Partners, LP Joint filing with ADAR1 Capital Management, LLC (6.21%), ADAR1 Capital Management GP, LLC (6.21%) and 1 more | 1,824,063 | 6.21% | 13G (passive) | Jan 23, 2024 |
| Rockledge Capital Corporation Joint filing with Lincoln Park Capital Fund, LLC (9.68%), Lincoln Park Capital, LLC (9.68%) and 3 more | 1,307,049 | 9.68% | 13G (passive) amendment | Dec 31, 2023 |
| Empery Asset Management, LP Joint filing with Ryan M. Lane (9.99%) | 864,090 | 9.99% | 13G (passive) | Jun 30, 2026 |
| Stonepine GP, LLC Joint filing with Stonepine Capital Management, LLC (9.90%), Stonepine Capital, L.P. (9.90%) and 1 more | 863,277 | 9.90% | 13G (passive) | May 4, 2026 |
| Devesh Gandhi Joint filing with SilverArc Capital Management, LLC (9.99%) | 851,285 | 9.99% | 13G (passive) | Jun 30, 2026 |
| Michelle Ross Joint filing with StemPoint Capital LP (9.90%), StemPoint Capital Management GP LLC (9.90%) | 845,740 | 9.90% | 13G (passive) | Jun 30, 2026 |
| Bleichroeder Holdings LLC Joint filing with Bleichroeder LP (9.99%), Andrew Gundlach (9.99%) | 808,300 | 9.99% | 13G (passive) | Jun 30, 2026 |
| Dmitry Balyasny Joint filing with Balyasny Asset Management L.P. (9.99%), Bam Gp LLC (9.99%) and 2 more | 798,382 | 9.99% | 13G (passive) | Jun 30, 2026 |
| Janus Henderson Group PLC | 798,382 | 9.99% | 13G (passive) | May 29, 2026 |
| Johnson David Edward Joint filing with Caligan Partners LP (5.90%) | 469,998 | 5.90% | 13G (passive) | Jun 30, 2026 |
| Aharon Gil Joint filing with Rosalind Advisors, Inc. (5.50%), Salamon Steven A J (5.50%) | 247,715 | 5.50% | 13G (passive) amendment | Dec 31, 2025 |
| Andrew Gundlach Joint filing with Bleichroeder LP (6.08%), Bleichroeder Holdings LLC (6.08%) | 200,000 | 6.08% | 13G (passive) | Sep 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CLRB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Caligan Partners LP | 469,998 | 4.97% | $1.31M | New | 0.06% |
| Nantahala Capital Management, LLC | 439,996 | 4.66% | $1.22M | New | 0.02% |
| Stempoint Capital LP | 354,938 | 3.76% | $986.73K | New | 0.17% |
| Vanguard Capital Management LLC | 327,367 | 3.46% | $910.08K | +245,483 | 0.00% |
| Silverarc Capital Management, LLC | 321,728 | 3.40% | $894.40K | New | 0.09% |
| Bleichroeder LP | 288,679 | 3.05% | $802.53K | +188,679 | 0.14% |
| Jupiter Topco LLC | 274,156 | 2.90% | $759.41K | New | 0.00% |
| Balyasny Asset Management L.P. | 220,000 | 2.33% | $611.60K | New | 0.00% |
| Empery Asset Management, LP | 189,605 | 2.01% | $527.10K | New | 0.61% |
| Diadema Partners LP | 138,341 | 1.46% | $384.59K | New | 0.05% |
| Stonepine Capital Management, LLC | 104,550 | 1.11% | $290.65K | New | 0.16% |
| Persistent Asset Partners Ltd | 92,983 | 0.98% | $258.49K | New | 0.08% |
| Boothbay Fund Management, LLC | 85,069 | 0.90% | $236.49K | New | 0.00% |
| Geode Capital Management, LLC | 53,351 | 0.56% | $148.32K | +573 | 0.00% |
| Vanguard Fiduciary Trust Co | 46,220 | 0.49% | $128.49K | +29,647 | 0.00% |
| Sequoia Financial Advisors, LLC | 21,850 | 0.23% | $60.74K | +3,000 | 0.00% |
| Acadian Asset Management LLC | 16,577 | 0.18% | $46.00K | New | 0.00% |
| Northern Trust Corp | 14,839 | 0.16% | $41.25K | New | 0.00% |
| Riverview Capital Advisers, LLC | 10,384 | 0.11% | $50.05K | – | 0.01% |
| BlackRock, Inc. | 4,735 | 0.05% | $13.16K | −10 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 29 | 3M | 36.8% | 14 / 6 | 2 / 4 | 3M | 0M |
| Q1 2026 | 19 | 0M | 3.3% | 4 / 2 | 3 / 4 | 0M | 0M |
| Q4 2025 | 20 | 0M | 3.7% | 4 / 7 | 1 / 5 | 0M | 0M |
| Q3 2025 | 21 | 0M | 3.1% | 6 / 7 | 3 / 4 | 0M | 0M |
| Q2 2025 | 19 | 0M | 1.1% | 19 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
7 funds held CLRB in Q2 2026, 90% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CLRB | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 184,145 | 1.95% | $511.92K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 143,222 | 1.52% | $398.16K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 26,977 | 0.29% | $84.71K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 5,641 | 0.06% | $17.71K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 2,064 | 0.02% | $6.48K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 200 | 0.00% | $628 | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 1 | 0.00% | $3 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| James V. Caruso | President & CEO, Director | 20,318 | 0.21% | Jul 8, 2026 |
| Jarrod Longcor | Chief Operating Officer | 20,451 | 0.22% | Jul 8, 2026 |
| Chad J. Kolean | CFO | 6,418 | 0.07% | Jul 8, 2026 |
| John Neis | Director | 10 | 0.00% | Jul 8, 2026 |
| Asher Chanan-Khan | Director | – | – | Jul 8, 2026 |
| Andrew Gu | Director | – | – | Jul 8, 2026 |
| Frederick W. Driscoll | Director | 19,417 | 0.21% | Jul 8, 2026 |
| Douglas J. Swirsky | Director | 25,000 | 0.26% | Jul 8, 2026 |
| Stefan Loren | – | – | – | Jul 10, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jarrod Longcor Chief Operating Officer | May 7, 2026 | Buy | +8,680 | $2.88 | $25.00K | 20,451 |
| James V. Caruso Chief Executive Officer, Director | May 7, 2026 | Buy | +8,680 | $2.88 | $25.00K | 20,318 |
| John Neis Director | Dec 12, 2025 | Sale | −198 | $3.70 | $733 | 10 |
| James V. Caruso Chief Executive Officer, Director | Jul 2, 2025 | Buy | +10,000 | $4.99 | $49.90K | 11,638 |
| Jarrod Longcor Chief Operating Officer | Jul 2, 2025 | Buy | +10,000 | $4.99 | $49.90K | 12,768 |
| Chad J. Kolean Chief Financial Officer | Jul 2, 2025 | Buy | +5,000 | $4.99 | $24.95K | 6,418 |
| Jarrod Longcor Chief Operating Officer | Jan 10, 2025 | Buy | +30,000 | $0.28 | $8.40K | 83,141 |
| Darrell Shane Lea Chief Commercial Officer | Dec 8, 2023 | Award | +39,599 | – | – | 39,599 |
| James V. Caruso President and CEO, Director | Dec 8, 2023 | Award | +40,596 | – | – | 49,236 |
| Chad J. Kolean Chief Financial Officer | Dec 8, 2023 | Award | +42,554 | – | – | 42,578 |
| Andrei Shustov Senior Vice President, Medical | Dec 8, 2023 | Award | +47,856 | – | – | 55,038 |
| Jarrod Longcor Chief Operating Officer | Dec 8, 2023 | Award | +42,927 | – | – | 53,141 |
| Douglas J. Swirsky Director | Sep 14, 2021 | Buy | +25,000 | $1.04 | $26.00K | 25,000 |
| Frederick W. Driscoll Director | Sep 3, 2021 | Buy | +19,417 | $1.04 | $20.19K | 19,417 |
| James V. Caruso President and CEO, Director | Mar 4, 2021 | Buy | +5,100 | $1.70 | $8.67K | 86,401 |
| Jarrod Longcor Chief Business Officer | Dec 28, 2020 | Buy | +29,630 | $1.35 | $40.00K | 102,148 |
| James V. Caruso President and CEO, Director | Dec 28, 2020 | Buy | +37,037 | $1.35 | $50.00K | 81,301 |
| Dov Elefant Chief Financial Officer | Dec 28, 2020 | Buy | +7,407 | $1.35 | $10.00K | 11,755 |
| Dov Elefant Chief Financial Officer | Jun 5, 2020 | Buy | +4,348 | $1.15 | $5.00K | 4,348 |
| Jarrod Longcor Chief Business Officer | Jun 5, 2020 | Buy | +65,218 | $1.15 | $75.00K | 72,518 |
| James V. Caruso President and CEO, Director | Jun 5, 2020 | Buy | +21,740 | $1.15 | $25.00K | 44,264 |
| Stephen A. Hill Director | Jun 4, 2020 | Buy | +18,000 | $1.08 | $19.44K | 18,000 |
| James V. Caruso President and CEO, Director | Feb 3, 2020 | Award | +100,000 | $2.71 | $271.00K | 100,000 |
| Dov Elefant Chief Financial Officer | Feb 3, 2020 | Award | +10,000 | $2.71 | $27.10K | 10,000 |
| Jarrod Longcor Chief Business Officer | Feb 3, 2020 | Award | +40,000 | $2.71 | $108.40K | 40,000 |
| Jarrod Longcor Chief Business Officer | Feb 28, 2019 | Buy | +100 | $2.00 | $200 | 7,300 |
| James V. Caruso President and CEO, Director | Nov 30, 2018 | Buy | +1,000 | $2.28 | $2.28K | 22,354 |
| Stephen A. Hill Director | Nov 29, 2018 | Sale | −939 | $2.21 | $2.08K | 53 |
| Stephen A. Hill Director | Nov 29, 2018 | Sale | −53 | $2.21 | $117 | 0 |
| Jarrod Longcor Chief Business Officer | Aug 16, 2018 | Buy | +500 | $2.71 | $1.36K | 7,200 |
| Jarrod Longcor Chief Business Officer | Mar 13, 2018 | Sale(10b5-1 plan) | −13,000 | $1.18 | $15.34K | 67,000 |
| James V. Caruso President and CEO, Director | Mar 12, 2018 | Sale(10b5-1 plan) | −34,000 | $1.20 | $40.80K | 213,548 |
| John Neis Director | Nov 14, 2017 | Sale | −5,214 | $1.49 | $7.77K | 626,103 |
| James V. Caruso President and CEO, Director | Apr 18, 2017 | Award | +200,000 | – | – | 247,548 |
| Jarrod Longcor Sr. VP of Corp Dev & Ops | Apr 18, 2017 | Award | +80,000 | – | – | 80,000 |
| Chad J. Kolean VP, Chief Financial Officer | Apr 18, 2017 | Award | +80,000 | – | – | 80,000 |
| John E. Friend II VP, Chief Medical Officer | Apr 17, 2017 | Award | +100,000 | – | – | 100,000 |
| John Neis Director | Nov 29, 2016 | Buy | +333,333 | $1.49 | $496.67K | 631,317 |
| Richard Hertzberg – | Oct 31, 2016 | Sale | −21,000 | $2.03 | $42.63K | 280,000 |
| Richard Hertzberg – | Apr 21, 2016 | Buy | +3,758 | $1.90 | $7.14K | 301,000 |
| James V. Caruso President and CEO, Director | Apr 20, 2016 | Buy | +46,948 | $2.12 | $99.53K | 47,548 |
| Paul L. Berns Director | Apr 20, 2016 | Buy | +117,371 | $2.12 | $248.83K | 117,371 |
| John Neis Director | Apr 20, 2016 | Buy | +234,742 | $2.12 | $497.65K | 297,984 |
| Stephen A. Hill Director | Apr 20, 2016 | Buy | +9,390 | $2.12 | $19.91K | 9,920 |
| Richard Hertzberg – | Apr 15, 2016 | Buy | +234,742 | $2.12 | $497.65K | 297,242 |
| AWM Investment Company, Inc. 10% owner | Dec 31, 2015 | Sale | −35,253 | $0.70 | $24.68K | 0 |
| AWM Investment Company, Inc. 10% owner | Dec 30, 2015 | Sale | −64,747 | $0.69 | $44.68K | 35,253 |
| AWM Investment Company, Inc. 10% owner | Dec 29, 2015 | Sale | −82,847 | $0.69 | $57.16K | 100,000 |
| Richard Hertzberg 10% owner | Dec 28, 2015 | Buy | +75,000 | $0.72 | $54.00K | 75,000 |
| AWM Investment Company, Inc. 10% owner | Dec 28, 2015 | Sale | −150,975 | $0.69 | $104.17K | 182,847 |
| Richard Hertzberg 10% owner | Dec 24, 2015 | Buy | +50,000 | $0.79 | $39.50K | 50,000 |
| AWM Investment Company, Inc. 10% owner | Dec 24, 2015 | Sale | −216,991 | $0.76 | $164.91K | 333,822 |
| Richard Hertzberg 10% owner | Dec 22, 2015 | Buy | +5,000 | $0.91 | $4.55K | 5,000 |
| AWM Investment Company, Inc. 10% owner | Dec 22, 2015 | Sale | −7,938 | $0.90 | $7.14K | 550,813 |
| AWM Investment Company, Inc. 10% owner | Dec 21, 2015 | Sale | −20,621 | $0.92 | $18.97K | 558,751 |
| AWM Investment Company, Inc. 10% owner | Dec 18, 2015 | Sale | −7,000 | $0.90 | $6.30K | 579,372 |
| AWM Investment Company, Inc. 10% owner | Dec 17, 2015 | Sale | −18,240 | $0.88 | $16.05K | 586,372 |
| Richard Hertzberg 10% owner | Dec 16, 2015 | Buy | +19,592 | $0.91 | $17.83K | 19,592 |
| AWM Investment Company, Inc. 10% owner | Dec 16, 2015 | Sale | −52,985 | $0.86 | $45.57K | 604,612 |
| AWM Investment Company, Inc. 10% owner | Dec 15, 2015 | Sale | −44,965 | $0.82 | $36.87K | 657,597 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Cellectar Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 7,797 shares on Oct 13, 2026 over the last 90 days.
See a number that looks wrong?